Which drug class blocks the action of leukotrienes to help manage asthma?

Leukotriene modifiers are specifically designed to block the action of leukotrienes, which are inflammatory mediators involved in the pathophysiology of asthma. By inhibiting leukotriene receptors or the synthesis of leukotrienes, these medications help reduce bronchoconstriction, mucus secretion, and airway inflammation. This action can lead to improved respiratory function and lower the frequency of asthma exacerbations.

The other drug classes mentioned do play roles in asthma management but do not directly block leukotrienes. Long-acting beta agonists (LABAs) work by relaxing the muscles around the airways, thereby improving airflow, but they do not affect leukotriene activity. Oral corticosteroids and inhalable corticosteroids reduce inflammation in the airways through different mechanisms, primarily by suppressing overall immune response and inflammatory processes, but they do not specifically target leukotrienes. Therefore, leukotriene modifiers are the only class among the choices that directly antagonize the effects of leukotrienes.